Raj Kannan
2021
In 2021, Raj Kannan earned a total compensation of $3.5M as Chief Executive Officer and Director at Aerie Pharmaceuticals.
Compensation breakdown
| Option Awards | $1,750,004 |
|---|---|
| Salary | $24,306 |
| Stock Awards | $1,750,000 |
| Total | $3,524,310 |
Kannan received $1.8M in option awards, accounting for 50% of the total pay in 2021.
Kannan also received $24.3K in salary and $1.8M in stock awards.
Rankings
In 2021, Raj Kannan's compensation ranked 3,793rd out of 12,415 executives tracked by ExecPay. In other words, Kannan earned more than 69.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,793 out of 12,415 | 69th |
Division Manufacturing | 1,551 out of 5,505 | 72nd |
Major group Chemicals And Allied Products | 630 out of 2,375 | 74th |
Industry group Drugs | 559 out of 2,096 | 73rd |
Industry Biological Products, Except Diagnostic Substances | 148 out of 449 | 67th |
Source: SEC filing on April 26, 2022.
Kannan's colleagues
We found seven more compensation records of executives who worked with Raj Kannan at Aerie Pharmaceuticals in 2021.
2021
Vicente Anido
Aerie Pharmaceuticals
Chief Executive Officer
2021
Thomas Mitro
Aerie Pharmaceuticals
Chief Operating Officer
2021
Casey Kopczynski
Aerie Pharmaceuticals
Chief Innovation Officer, Head of Research and External Innovation
2021
John LaRocca
Aerie Pharmaceuticals
General Counsel
2021
Benjamin McGraw
Aerie Pharmaceuticals
Former Interim Executive Chair
2021
Richard Rubino
Aerie Pharmaceuticals
Chief Financial Officer
2021
Christopher Staten
Aerie Pharmaceuticals